Study of REGN5668 with or without immunotherapy in ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has had at least one prior platinum-based chemotherapy treatment (except carcinosarcoma)
- If you’re in an “expansion” group, have at least one tumor spot that can be measured on scans (measurable lesion)
- Have higher-than-normal tumor marker CA-125 (at least 2 times the upper limit), unless you’re in an endometrial-only group
- Be able to do daily activities fairly well (ECOG performance status 0 or 1) and expect at least 3 months of life
- Have enough blood, kidney, liver, and bone marrow function based on lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.